TIGHTENING PRRS STRINGS
More than three decades after the identification of porcine reproductive and respiratory syndrome (PRRS) in the United States, the virus continues to ravage swine herds, resulting in estimated losses that could be as high as $664 million per year.1 Controlling PRRS requires diligent biosecurity measures, a focus on growing the healthiest pigs and a strong protocol that involves planning ahead — and being prepared for challenges.
PROTECT YOUR BARN
PRRS is very opportunistic and contagious, continually looking for ways into your operation. The foundational defense has to be an intentional biosecurity plan properly implemented with your team. This plan should include layers — no one action can prevent all disease exposure, but a combination of efforts can help plug the holes when PRRS sneaks in.
People Movement
Vehicles & Deliveries
Swine Movement
Air & Water
DUAL IMMUNITY
Combined with your biosecurity protocol, vaccinations can help protect your pigs from this durable virus by building their immunity. And like biosecurity, a layered approach may help boost your protection.
INNATE IMMUNITY
A non-specific line of protection against pathogens, constituted by physical, chemical or cellular barriers.
ADAPTIVE IMMUNITY
Develops following exposure to an antigen, either by infection or vaccination. It is specific and long-lasting.
Elanco offers both killed autogenous and MLV vaccine solutions that work together to protect young piglets in the crate and prepare them for the nursery transition. Given at processing, the Barricade® Platform, delivered intranasally, stimulates both innate immunity through the mucosa of the respiratory tract and adaptive immunity by delivering the specific PRRS virus back to the pig. This solution focuses on providing the piglets with very early protection, while Prevacent® PRRS MLV administered at weaning can serve to boost immunity before sending them off to the nursery.
To supplement your vaccine protocol, non-antibiotic, water-soluble Swine Awake™ awakens a cell-mediated immune response that prepares a pig's immunity before a viral challenge.2 The additional immunity boost ahead of a PRRS challenge increases the likelihood of improved pig livability.3
IN CASE OF A BREAK
If PRRS does find its way through your defenses, Elanco has a toolkit of solutions and services, backed by experienced technical experts to support your team in getting your barn stabilized and back on track for your operation’s goals.
Swine Awake is not intended to treat PRRS or SRD.
Your PRRS needs are not static, but evolving, and we are continuously learning more information about the virus and ways to prevent and mitigate the impact. We are always striving to provide our customers with reliable products, unparalleled service and technical support to combat PRRS and its impact on our industry.
The labels contain complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.
PULMOTIL® AC IMPORTANT SAFETY INFORMATION:
Before using this product, it is important to read the entire product insert, including the boxed human warning.
WARNING: Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin. Avoid direct skin and eye contact. In case of human exposure, call 1-800-722-0987 and consult a physician immediately.
• Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
• For use only in swine. Not for injection. Injection of tilmicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.
• Swine intended for human consumption must not be slaughtered within 7 days of treatment.
• Always treat the fewest number of animals necessary to control a respiratory disease outbreak. Prescriptions shall not be refilled.
• Concurrent use of Pulmotil AC and another macrolide by any route, or use of another macrolide immediately following this use of Pulmotil AC is not advised.
• Ensure that pigs have continuous access to medicated water during the treatment period. Monitor pigs for signs of water refusal and dehydration while being treated.
BAYTRIL® IMPORTANT SAFETY INFORMATION:
CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this drug in food-producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.
• Not for use in humans. Keep out of reach of children.
• Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes.
• In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures.
• Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.
INCREXXA™ IMPORTANT SAFETY INFORMATION:
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.
• Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.
• The effects of Increxxa on porcine reproductive performance, pregnancy, and lactation have not been determined.
• Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
• Store below 25°C (77°F), with excursions up to 40°C (104°F).
• 100 mL: Use within 2 months of first puncture and puncture a maximum of 67 times. If more than 67 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.
• 250 mL and 500 mL: Use within 2 months of first puncture and puncture a maximum of 100 times. If more than 100 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.
